Why is Glenmark Pharma falling/rising?

As of 15-Sep, Glenmark Pharmaceuticals Ltd. is currently priced at 2,098.35, reflecting a decrease of 26.3 points or 1.24%. The stock has underperformed its sector by 0.79% today, despite trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, Glenmark has shown a positive return of 2.32%, and it has delivered a substantial year-to-date return of 30.43%. However, there has been a decline in investor participation, with delivery volume falling by 6.85% against the 5-day average. The company's strong ability to service debt, indicated by a low Debt to EBITDA ratio of 1.00 times, and high institutional holdings at 38.3% suggest a solid foundation, contributing to its consistent returns over the last three years.
In the broader market context, Glenmark's recent performance contrasts with the Sensex, which has gained 1.24% over the past week. While Glenmark has outperformed the benchmark over longer periods, including a 20.25% return in the last year, the current decline may reflect short-term market pressures or profit-taking by investors. Despite the recent drop, the stock's liquidity remains adequate for trading, indicating that while there may be fluctuations, the overall market sentiment towards Glenmark remains cautiously optimistic due to its historical performance and strong fundamentals.